Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model | Zendy

Anthony D. Kang | Zendy; Kenny Smith | Zendy; Anders H. Berg | Zendy; Katherine A. Truelson | Zendy; George M. Eliopoulos | Zendy; Christopher McCoy | Zendy; James E. Kirby | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model

Author(s) -

Anthony D. Kang,

Kenny Smith,

Anders H. Berg,

Katherine A. Truelson,

George M. Eliopoulos,

Christopher McCoy,

James E. Kirby

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02585-17

Subject(s) - acinetobacter baumannii , microbiology and biotechnology , aminoglycoside , multiple drug resistance , cmax , antibiotics , leukopenia , biology , medicine , pharmacokinetics , pharmacology , chemotherapy , bacteria , pseudomonas aeruginosa , genetics

Apramycin, an aminocyclitol aminoglycoside, was rapidly bactericidal againstAcinetobacter baumannii . In a neutropenic murine thigh infection model, treatment-associatedA. baumannii CFU reductions of >4 log10 per thigh were observed for all exposures for which area under the curve (AUC)/MIC ratio was >50 and maximum concentration of drug in serum (C max )/MIC was ≈10 or higher. Based on these findings, we suggest that apramycin deserves further preclinical exploration as a repurposed therapeutic for multidrug-resistant Gram-negative pathogens, includingA. baumannii .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research